DupCheck is a web-based tool used globally to screen for duplicate
patients in clinical trials across studies, sponsors and therapeutic areas.
Duplicate enrollment harms both patients and studies.In many therapeutic
areas even a small number of duplicate patients can lead to a negative or
failed trial. In addition enrolling duplicate patients can result in a
misattributed serious adverse event.
DupCheck is part of NEWMEDS an international consortium of scientists
that has launched one of the largest ever research academic-industry
collaboration projects to find new methods for the development of drugs.
NEWMEDS brings together top scientists from academic institutions with a
wide range of expertise, and partners them with nearly all major
biopharmaceutical companies. NEWMEDS ultimate goal is to develop new
approaches for shorter and more efficient trials of new medications.
DupCheck provides sites and sponsors with real time information on
attempted duplicate enrollment at time of screening. DupCheck can also
screen for previous participation in a trial of investigational drug.
DupCheck can be linked to existing electronic data capture
systems—eliminating additional data entry—and run in the background, analogues
to an anti-virus.
DupCheck is compliant with EU
General Data Protection Regulation (GDPR) and HIPAA. No identifiable patient or sponsor data is transmitted, stored or shared.
DupCheck was given a favorable Qualification Advice review by the European Medicines Agency and the FDA has stated that DupChecking is advisable.
Integration
DupCheck is available for integration with:
DupCheck is an ACRES ally
For more information, sponsors, investigators and regulators please contact us
at: Contact@DupCheck.org
Core Team
Founding Director
Jonathan Rabinowitz, PhD is the founding director of
DupCheck. He is the Elie Wiesel
Professor at Bar Ilan University and a visiting professor at Mount Sinai School
of Medicine in New York. His research
focuses on improving efficiency of clinical trials. He has over 25 years of experience in
managing and analyzing large data sets and in developing and implementing
statistical algorithms in pharmaceutical, services and epidemiological datasets. He is the academic lead of
the Advanced Data
Analysis Techniques group at IMI/EFPIA sponsored NEMWEDS, one of the largest
ever research academic-industry collaboration projects directed at finding
new methods for drug development. He did
doctoral training in Statistics at Bar Ilan University and in Social Welfare at
Yeshiva University. He serves on
advisory groups at FDA and EMA. He is a
member of the American College of Neuropsychopharmacology. He is on the Executive Committee of
International Society for CNS Clinical
Trials and Methodology and also serves as co-chair of the working group on
consistency in measurement. He has
served as a member of the DIA Scientific Working Group on Missing Data in
Clinical Trials. He has over 170
scientific publications.
Chief Technology Officer
Mr. Alexey Abraham has over 20 years of software development experience. Among them 8 years in product and project management of complex software projects in different countries.
The companies, he has worked for include: Intel, Orange UK, Comverse, NOVA, Matrix, Zoral Labs, Gat Systems, FinalView, Towndwarf Co., Control&Robotics Solutions.
Alexey has vast experience in server side and front end development, computer security, complex web systems, mobile development for different platforms, low level programming for Windows & Linux, surveilance and image recognition systems, banking.
Lead Developer
Yosef Stefansky, has extensive software
development and project management experience.
He held developer and team positions in the Israel Defense Forces (IDF) and Israel Aerospace Industries (IAI). Mr. Stefansky has deep pockets of expertise in high security database architecture and system
security.
Legal Services
Gross, Kleinhendler, Hodak, Halevy, Greenberg & Co.
www.gkh-law.com
